Bruker's Stock Plunge an Over-Reaction

by H.S. Ayoub
BioHealth Investor.com



Well, it seems that a comment I had made earlier, "Bear Stearns knows something, and it is making me nervous," might have been an over-reaction on my part. As much of an over-reaction as was seen on Wall Street Tuesday after Bruker BioSciences (BRKR) stock plunged more than 20% following a pretty decent earnings report.

It seems that Bear Stearns released an opinion report to its clients following the conference call saying that while earings were good, the stock is over-valued according to their valuation models.

The stock price sits at $9.08 as of noon Wednesday, still a decent gain from February's $7.70 stock offering, and a little lower than my entry point of $9.42.

Given the polarizing effects of the Bear Stearns report and the stock offering, it seems that Bruker's stock might hover in this $9 range for a while.


Source: BioHealth Investor.com



RELATED READING:
- Bruker's Profits Increase, So Why the 20% Drop?
- Bruker BioSciences: Earnings Growing, Insiders Buying

______________________